Clinical Trial
Published on 04 Apr 2023
Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer
in Thoracic Oncology
![Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer](https://www.frontiersin.org/files/myhome article library/1081729/1081729_Thumb_400.jpg)
- 3,347 views
- 2 citations